The DPP8 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, engineered for disruption of the DPP8 gene. This heterogeneous pool provides a robust loss-of-function model to study DPP8-dependent processes without clonal artifacts, useful for investigating immune regulation, apoptosis, and cell adhesion.
A-549 cells, isolated from a 58-year-old Caucasian male with lung adenocarcinoma, serve as a model of alveolar type II pneumocytes, exhibiting surfactant production and barrier functions. They are widely used for research on lung epithelial biology, innate immunity, and oncogenic signaling due to their well-characterized properties and experimental tractability.
DPP8 is a serine exopeptidase that cleaves N-terminal dipeptides from substrates with penultimate proline, thereby regulating peptide-mediated signaling. Its loss leads to activation of the NLRP1 and CARD8 inflammasomes, resulting in caspase-1-dependent processing of pro-IL-1?? and pro-IL-18 and pyroptotic cell death. DPP8 disruption also induces RIPK1-dependent apoptosis, involving caspase-8. DPP8 interacts with Hsp90 and proteasome components, and its downstream effectors include ASC, NLRP1, CARD8, and mature IL-1??/IL-18. Thus, DPP8 occupies a pivotal position linking proteolytic activity to inflammatory and cell death pathways.
In the A-549 lung adenocarcinoma context, DPP8 knockout enables dissection of how alveolar epithelial cells orchestrate inflammasome responses and apoptosis. Given the roles of DPP8 in cancer and inflammatory diseases, this model is relevant for studying inflammation-driven tumor progression and for evaluating DPP8 as a therapeutic target. It also permits investigation of epithelial barrier regulation under stress.
Applications include inflammasome biology studies using LDH release and IL-1??/IL-18 secretion assays, and apoptosis assessment via Annexin V staining. Enzymatic activity assays confirm DPP8 disruption, while co-immunoprecipitation can map protein interactions with Hsp90 or inflammasome components. RNA-seq enables transcriptome-wide profiling. These cells are suitable for drug target validation and inhibitor screening. For further information, please contact Ascent Research.
